Zhaleiko, I.O.; Perekhrestenko, T.P.; Bilko, D.I.; Dyagil, I.S.; Bilko, N.M.
(Experimental Oncology, 2014)
Background: Targeted therapy drugs, including imatinib, are used for inhibiting the marker oncoprotein of chronic myeloid leukemia — BCR-ABL tyrosine kinase. However, in some patients the drug resistance can emerge too ...